Skip to content

Medical emergency? What to do

Vioxx risks confirmed by new studies

3-RXPublished September 14, 20063 min read

Key points

  • The use of Vioxx (rofecoxib), the anti-inflammatory drug at the center of many high-profile lawsuits, does, in fact, increase the risk of heart attacks and strokes and may also adversely affect kidney function, according to the results of two studies released early by the Journal of the American Medical Association.
  • Jingjing Zhang, from Harvard Medical School in Boston, and colleagues conducted an analysis of data from clinical trials to compare the kidney and heart rhythm risks associated with COX-2 inhibitors, including Vioxx, Celebrex (celecoxib), and others.
  • Compared with inactive "placebo" drug, Vioxx was associated with a nearly threefold increased risk of heart rhythm disturbances, or "arrhythmias.
  • David Henry, from the University of Newcastle in New South Wales, Australia, conducted a review of observational studies to assess the cardiovascular risks associated with COX-2 inhibitors and with older non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen and ibuprofen.

The use of Vioxx (rofecoxib), the anti-inflammatory drug at the center of many high-profile lawsuits, does, in fact, increase the risk of heart attacks and strokes and may also adversely affect kidney function, according to the results of two studies released early by the Journal of the American Medical Association.

Both reports suggest that only Vioxx, not other COX-2 inhibitors, markedly raises the risk of these events.

Dr. Jingjing Zhang, from Harvard Medical School in Boston, and colleagues conducted an analysis of data from clinical trials to compare the kidney and heart rhythm risks associated with COX-2 inhibitors, including Vioxx, Celebrex (celecoxib), and others. A search of medical databases yielded 114 relevant trials with 116,094 participants.

A total of 6,394 adverse kidney events and 286 heart rhythm disturbances occurred in the study group. Statistical analysis suggested no evidence that all COX-2 inhibitors produced these side effects.

Compared with inactive "placebo" drug, Vioxx was associated with a nearly threefold increased risk of heart rhythm disturbances, or "arrhythmias." In addition, use of the drug was tied to elevated risks of kidney problems.

By contrast, Celebrex use appeared to cut the risk of kidney dysfunction and high blood pressure by 39 and 17 percent, respectively, compared with the placebo. The other COX-2 inhibitors had no significant effect on the risk of arrhythmias or kidney problems, the authors note.

In the second report, Dr. Patricia McGettigan and Dr. David Henry, from the University of Newcastle in New South Wales, Australia, conducted a review of observational studies to assess the cardiovascular risks associated with COX-2 inhibitors and with older non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen and ibuprofen. Their database search yielded 7,086 potential studies, of which 23 were deemed eligible for analysis.

At doses greater than 25 mg per day, Vioxx more than doubled the risk of heart attack and stroke. At lower doses, the drug was associated with a 33-percent increased risk. These risks were apparent within the first month of treatment.

By contrast, at commonly used doses, Celebrex did not raise the risk of heart attack or stroke, the investigators point out.

The older NSAIDs generally had little effect on cardiovascular risk, the exception being diclofenac, which was associated with a 40-percent increased risk. Contrary to some reports, naproxen use did not appear to reduce the risk of heart attack or stroke.

In a related editorial, Dr. David J. Graham, from the US Food and Drug Administration in Silver Spring, Maryland, comments that the two reports "provide clarity on a topic that has been dominated more by disinformation than reason."

Graham mentions that Vioxx-maker Merck is now seeking US approval of etoricoxib, a COX-2 inhibitor already approved for use in Europe and elsewhere.

The concern is that the major study (MEDAL), which showed etoricoxib to be safe, compared the drug against diclofenac, an agent that has now been tied to heart attack and stroke in two review studies.

"From the perspective of patient safety and rational therapeutics, naproxen, not diclofenac, should have been the reference drug in MEDAL," Graham notes. "Had that been so, it is highly likely that etoricoxib would have been shown to be no different that its first-cousin rofecoxib with respect to cardiovascular risks."

SOURCE: Journal of the American Medical Association, October 4, 2006.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug Abuse
Cancer

EU to take another look at GSK breast cancer drug

Europe's drugs regulators will take another look at GlaxoSmithKline Plc's new breast cancer pill Tyverb after new data showed a small risk of higher liver enzymes during treatment with the drug. GSK, Europe's biggest…

2 min read

Drug Abuse

Study raises caution on new painkillers

A new class of painkillers that block a receptor called TRPV1 may interfere with brain functions such as learning and memory, a new study suggests. The experiments with rat brain found that the TRPV1 receptor…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.